CD20 x CD3 Bispecific Antibodies in Non-Hodgkin Lymphoma Management

The speakers explore the potential efficacy and side effect profiles of CD20 x CD3 bispecific antibodies in the management of non-Hodgkin lymphoma. They discuss the optimal partner for combination therapy, address the issue of susceptibility to infection and response to vaccination, and emphasize the importance of educating patients and staff and implementing prophylaxis measures.